H.C. Wainwright raised the firm’s price target on Dyne Therapeutics (DYN) to $46 from $38 and keeps a Buy rating on the shares. The firm believes Dyne’s dual Breakthrough programs in myotonic dystrophy and Duchenne muscular dystrophy are now entering registrational stages with “validated functional and biomarker data. This positions the company for clinical catalysts and as a strategic takeover asset, the analyst tells investors in a research note. The Avidity acquisition “sets a clear benchmark, and Dyne’s more mature dataset strengthens the case for a higher premium takeout,” contends H.C. Wainwright.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DYN:
- Positive Outlook for Dyne Therapeutics: Strong Financial Performance and Promising Clinical Developments Support Buy Rating
- Dyne Therapeutics Advances in Neuromuscular Disease Therapies
- Dyne Therapeutics reports Q3 EPS (76c), consensus (85c)
- Dyne Therapeutics announces Z-rostudirsen remains on track for 1Q27 launch
- Dyne Therapeutics Advances DYNE-101 Study for Myotonic Dystrophy Type 1